Ozmosi | Gramicidin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Gramicidin

Alternative Names: gramicidin, neo-polycin, neosporin
Clinical Status: Inactive
Latest Update: 2025-07-23
Latest Update Note: News Article

Product Description

Gramicidin A is an antimicrobial peptide that destroys gram-positive bacteria. The bactericidal mechanism of antimicrobial peptides has been linked to membrane permeation and metabolism disruption as well as interruption of DNA and protein functions. However, the exact bacterial killing mechanism of gramicidin A is not clearly understood. Gramicidin A induced membrane permeabilization and changed the composition of the membrane. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25622083/)

Mechanisms of Action: Gram+ Bacteria Inhibitor, Gram- Bacteria Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Topical

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | Denmark | Dominican Republic | Egypt | Finland | Germany | Hong Kong | India | Indonesia | Ireland | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Spain | Sweden | Taiwan | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated